Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 4/2018

01-12-2018 | Systemic Therapies (M Liu and T Haddad, Section Editors)

Novel Agents for the Management of Endocrine Resistant Breast Cancer

Authors: Sonya Reid-Lawrence, Ingrid A. Mayer

Published in: Current Breast Cancer Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

Most women with hormone receptor (HR)-positive, HER2-negative (HR+/HER2−) breast cancer will ultimately develop endocrine-resistant disease, either primary or acquired. This review will discuss the proposed mechanisms underlying endocrine resistance and key advances in the treatment of endocrine-resistant breast cancer.

Recent Findings

Estrogen receptor 1 mutations (ESR1) occur in the majority of patients with HR+/HER2− metastatic breast cancer after prolonged exposure to aromatase inhibitors. Data from the SoFEA trial showed that patients had improved progression-free survival (PFS) after taking fulvestrant compared with exemestane. Fulvestrant is currently the only selective estrogen receptor degrader (SERD) available and development of oral novel SERDs with higher bioavailability and potency are currently being investigated.

Summary

Despite significant advances in the treatment of HR+/HER2− breast cancer over the past four decades, a significant proportion of patients do still develop endocrine resistance following optimal endocrine therapy. In this review, we aim to provide an overview of the different classes of novel agents currently being investigated to overcome endocrine resistance.
Literature
1.
Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer – an overview and update. Mol Cell Endocrinol. 2015;418:220–34.CrossRef
2.
•• Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. 2016;375(20):1925–36. This was an important landmark trial that led to the first CDK4/6 inhibitor being granted FDA approval as a first-line option for patients with HR+/HER2− metastatic breast cancer, in combination with an AI.
3.
Mancuso MR, Massarweh SA. Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer. Curr Probl Cancer. 2016;40(2):95–105.CrossRef
4.
Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, et al. Prevalence of esr1 mutations in cell-free dna and outcomes in metastatic breast cancer: a secondary analysis of the bolero-2 clinical trial. JAMA Oncology. 2016;2(10):1310–5.CrossRef
5.
Salkeni MA, Hall SJ. Metastatic breast cancer: endocrine therapy landscape reshaped. Avicenna Journal of Medicine. 2017;7(4):144–52.CrossRef
6.
Balko JM (2017) ESR1 mutations associated with acquired resistance to antiestrogen therapy
7.
Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res. 2015;17:40.CrossRef
8.
Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero J-M, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718–24.CrossRef
9.
Dixon JM. Endocrine resistance in breast cancer. J New Journal of Science. 2014;2014:27.
10.
Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol (London, England). 2012;8(6):651–7.CrossRef
11.
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol. 2014;25(12):2357–62.CrossRef
12.
Saksena R, Wong ST. Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer. Breast cancer (Dove Medical Press). 2013;5:27–35.
13.
Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized phase II trial of Fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. 2018;36(16):1556–63.CrossRef
14.
Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, et al. A phase Ib study of alpelisib (BYL719), a PI3Kα-specific inhibitor, with letrozole in ER+/HER2-negative metastatic breast cancer. Clin Cancer Res. 2017;23(1):26–34.CrossRef
15.
Baselga J, Im S-A, Iwata H, Cortés J, De Laurentiis M, Jiang Z, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904–16.CrossRef
16.
Di Leo A, Johnston S, Lee KS, Ciruelos E, Lonning PE, Janni W, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(1):87–100.CrossRef
17.
Baselga J, Dent SF, Cortés J, Im Y-H, Diéras V, Harbeck N, et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. 2018;36(18_suppl):LBA1006-LBA.
18.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. 2017;35(32):3638–46.
19.
Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive. Advanced Breast Cancer. 2016;375(18):1738–48.
20.
•• Fasching P, Jerusalem G, Pivot X, Martin M, De Laurentiis M, Blackwell K, et al. Abstract OT2-01-02: phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment: MONALEESA-3. 2016;76(4 Supplement):OT2-01-2-OT2--2. An important study that demonstrated that fulvestrant plus a CDK4/6 inhibitor can be used as a first-line option for patients with HR+/HER2− metastatic breast cancer.
21.
George W. Sledge J, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. 2017;35(25):2875–84.
22.
Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. PALOMA3: a double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. 2015;33(15_suppl):LBA502-LBA.
23.
• Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, A phase ii study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in Patients with refractory HR+,HER2- metastatic breast cancer. 2017;23(17):5218–24. This is the first study that showed a benefit for single-agent CDK4/6 inhibitor (abemaciclib) in patients that have progressed on endocrine therapy and chemotherapy.
24.
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–15.CrossRef
25.
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.CrossRef
26.
Hortobagyi GN, Paluch-Shimon S, Petrakova K, Villanueva C, Chan A, Nusch A, et al. First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses. 2018;36(15_suppl):1022-.
27.
Formisano L, Lu Y, Jansen VM, Bauer JA, Hanker AB, Sanders ME, et al. Abstract 1008: gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer. 2017;77(13 Supplement):1008-.
28.
Cortes J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez-MacGregor M. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: triplet combination-based endocrine therapies. Cancer Treat Rev. 2017;61:53–60.CrossRef
29.
Juric D, Ismail-Khan R, Campone M, García-Estévez L, Becerra C, De Boer R, et al. Abstract P3-14-01: phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: safety, preliminary efficacy and molecular analysis. 2016;76(4 Supplement):P3-14-01-P3-14-01.
30.
Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3(2):224–37.CrossRef
31.
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189–94.CrossRef
32.
Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, et al. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ breast cancer. 2018;4:1.CrossRef
33.
Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17):2128–35.CrossRef
34.
Rugo HS, Delord J-P, Im S-A, Ott PA, Piha-Paul SA, Bedard PL, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. 2018.
35.
Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria J-C, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13(12):e1002201.CrossRef
36.
Mayer E, Wander S, Regan M, DeMichele A, Forero A, Rimawi M, et al. Abstract OT3-05-11: palbociclib after CDK inhibitor and endocrine therapy (PACE): a randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer. 2018;78(4 Supplement):OT3–05-11-OT3–05-11.
37.
Toy W, Weir H, Razavi P, Berger M, Wong WL, De Stanchina E, et al. Abstract 863: differential activity and SERD sensitivity of clinical ESR1 mutations. 2016;76(14 Supplement):863-.
38.
Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor–Positive Advanced Breast Cancer 2016;34(25):2961–8.
39.
Weir HM, Bradbury RH, Lawson M, Rabow AA, Buttar D, Callis RJ, et al. AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models. Cancer Res. 2016;76(11):3307–18.CrossRef
40.
Dickler M, Bardia A, Mayer I, Winer E, Rix P, Hager J, et al. Abstract CT231: a first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer. 2015;75(15 Supplement):CT231-CT.
Metadata
Title
Novel Agents for the Management of Endocrine Resistant Breast Cancer
Authors
Sonya Reid-Lawrence
Ingrid A. Mayer
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 4/2018
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-018-0298-3

Other articles of this Issue 4/2018

Current Breast Cancer Reports 4/2018 Go to the issue

Clinical Trials (PF Peddi, Section Editor)

Updates on Molecular Classification of Triple Negative Breast Cancer

Risk and Prevention (ME Wood, Section Editor)

Non-hormonal Chemoprevention

Global Breast Cancer (BO Anderson and C Duggan, Section Editors)

Phased Implementation as a Strategy for Stepwise, Sustainable Improvement in Breast Healthcare in Low-Resource Settings

Systemic Therapies (M Liu and T Haddad, Section Editors)

Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer

Systemic Therapies (M Liu and T Haddad, Section Editors)

Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer

Clinical Trials (PF Peddi, Section Editor)

Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits